Literature DB >> 16002173

Oligonucleotide-protamine-albumin nanoparticles: Protamine sulfate causes drastic size reduction.

Gottfried Mayer1, Vitali Vogel, Jörg Weyermann, Dirk Lochmann, Jacomina A van den Broek, Christos Tziatzios, Winfried Haase, Daan Wouters, Ulrich S Schubert, Andreas Zimmer, Jörg Kreuter, Dieter Schubert.   

Abstract

Nanoparticles prepared by self-assembly from oligonucleotides (ONs), protamine free base, and human serum albumin ("ternary proticles") are spheres of diameters around 200 nm. Substitution of the protamine free base by protamine sulfate leads to proticles of only around 40 nm in diameter with otherwise unchanged properties. The availability of drug delivery systems of very similar composition but grossly different size may be advantageous when dealing with cells which show size-dependent particle uptake. These nanoparticles are promising candidates for ON delivery to cells because of the following reasons: (1) They are stable for several hours in solutions of up to physiological ionic strength; (2) they are efficiently taken up by cells; (3) after cellular uptake, they easily release the ONs even when these are present as phosphorothioates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002173     DOI: 10.1016/j.jconrel.2005.04.019

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  10 in total

Review 1.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

Review 2.  Nanoparticle-based technologies for retinal gene therapy.

Authors:  Jeffrey Adijanto; Muna I Naash
Journal:  Eur J Pharm Biopharm       Date:  2015-01-12       Impact factor: 5.571

3.  The novel albumin-chitosan core-shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation.

Authors:  Mahdi Karimi; Pinar Avci; Rezvan Mobasseri; Michael R Hamblin; Hossein Naderi-Manesh
Journal:  J Nanopart Res       Date:  2013-04-01       Impact factor: 2.253

4.  Characterization and performance of nucleic acid nanoparticles combined with protamine and gold.

Authors:  Robert K DeLong; Uzma Akhtar; Michael Sallee; Brooke Parker; Stephanie Barber; Jie Zhang; Michael Craig; Richard Garrad; Anthony J Hickey; Eric Engstrom
Journal:  Biomaterials       Date:  2009-09-01       Impact factor: 12.479

5.  EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins.

Authors:  Johannes Winkler; Patricia Martin-Killias; Andreas Plückthun; Uwe Zangemeister-Wittke
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261

6.  Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus.

Authors:  Dmitry Polyakov; Ekaterina Sinitsyna; Natalia Grudinina; Mariia Antipchik; Rodion Sakhabeev; Viktor Korzhikov-Vlakh; Mikhail Shavlovsky; Evgenia Korzhikova-Vlakh; Tatiana Tennikova
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

Review 7.  Use of Protamine in Nanopharmaceuticals-A Review.

Authors:  Ivana Ruseska; Katja Fresacher; Christina Petschacher; Andreas Zimmer
Journal:  Nanomaterials (Basel)       Date:  2021-06-07       Impact factor: 5.076

Review 8.  Protein nanoparticles as drug delivery carriers for cancer therapy.

Authors:  Warangkana Lohcharoenkal; Liying Wang; Yi Charlie Chen; Yon Rojanasakul
Journal:  Biomed Res Int       Date:  2014-03-20       Impact factor: 3.411

9.  Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration.

Authors:  Bernhard Scheicher; Cornelia Lorenzer; Katrin Gegenbauer; Julia Partlic; Fritz Andreae; Alexander H Kirsch; Alexander R Rosenkranz; Oliver Werzer; Andreas Zimmer
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

10.  Encapsulating TGF-β1 Inhibitory Peptides P17 and P144 as a Promising Strategy to Facilitate Their Dissolution and to Improve Their Functionalization.

Authors:  Nemany A N Hanafy; Isabel Fabregat; Stefano Leporatti; Maged El Kemary
Journal:  Pharmaceutics       Date:  2020-05-02       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.